Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)

Paclitaxel is a standard second‐line gastric cancer treatment in Japan. Trastuzumab could be active as second‐line chemotherapy for taxane/trastuzumab‐naïve patients with epidermal growth factor 2 (HER2)‐positive advanced gastric cancer. Patients aged ≥20 years with HER2‐positive, previously treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishikawa, Kazuhiro, Takahashi, Tsunehiro, Takaishi, Hiromasa, Miki, Akira, Noshiro, Hirokazu, Yoshikawa, Takaki, Nishida, Yasunori, Iwasa, Satoru, Miwa, Hiroto, Masuishi, Toshiki, Boku, Narikazu, Yamada, Yasuhide, Kodera, Yasuhiro, Yoshida, Kazuhiro, Morita, Satoshi, Sakamoto, Junichi, Saji, Shigetoyo, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129528/
https://www.ncbi.nlm.nih.gov/pubmed/27521503
http://dx.doi.org/10.1002/ijc.30383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129528/
https://www.ncbi.nlm.nih.gov/pubmed/27521503
http://dx.doi.org/10.1002/ijc.30383

Ejemplares similares